Avience Biomedicals IPO

The Avience Biomedicals SME IPO is open between 18 Jun 2026 and 22 Jun 2026, offered at a price band of ₹196–208 per share, and is set to list on NSE. The IPO seeks to raise ₹30.24 crore. Retail investors bid in lots of 600 shares, a minimum application of ₹2,49,600.

Issue structure

The IPO is structured entirely as a fresh issue of ₹28.53 crore, so the full proceeds flow to the company to fund its stated objects of the issue.

Objects of the issue

Per the offer document, the company intends to deploy the net proceeds primarily toward part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, sector 28 in the medical device park under the yamuna expressway industrial development authority (yeida), gautam buddha nagar, uttar pradesh (₹14.05 crore), alongside funding the working capital requirements of the company (₹8.25 crore). In all, 4 objects are disclosed — the full break-up is in the table above.

Financials

In FY2026, Avience Biomedicals reported revenue of ₹41.94 crore and a net profit of ₹5.74 crore. Revenue grew from ₹24.37 crore in FY2024 to ₹41.94 crore in FY2026 (+72.0%). Net worth stood at ₹28.52 crore at the end of FY2026.

Valuation

At the upper band, the issue is priced at 16.56× post-issue earnings and 3.68× book value, against a return on net worth of 49.89% and a debt-to-equity ratio of 0.97. These ratios come from the offer document and are for comparison, not a recommendation.

Promoters

The promoters of the company are Dharam Deo Choudhary, Ram Nagina Choudhary, Janardan Pal and Deepa Choudhary. Promoter holding stands at 87.89% before the issue and comes down to 64.59% after listing.

Grey market premium (GMP)

In the unofficial grey market, Avience Biomedicals shares are quoted at a premium of ₹145 implying an expected listing around ₹353, about +69.7% over the upper band. Grey market premium is a sentiment indicator set by private dealers, not the company or the exchange — it moves quickly and is not a reliable predictor of the actual listing price.

Subscription

The Avience Biomedicals IPO was subscribed 385.24 times overall. The strongest demand came from non-institutional investors (NII) at 597.23 times, with qualified institutional buyers (QIB) at 196.77× and retail investors at 401.21×.

Listing performance

Avience Biomedicals listed on 25 Jun 2026 at ₹395.2, a premium of +90.0% over the issue price of ₹208.

What to weigh

When evaluating the Avience Biomedicals IPO, the data points most investors look at are the fresh-issue-versus-OFS split, the revenue and profitability trend, subscription demand across investor categories and the grey market premium. Grey market premium and subscription figures reflect short-term sentiment rather than long-term fundamentals; the figures on this page are for information only and are not investment advice.

About Avience Biomedicals

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test. Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit. Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY. Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer. Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM). As of December 2024, the company had 65 permanent employees and 33 contractual employees Competitive Strength Strong Industry Experience and Expertise. Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits. Strong distribution network across India and is growing its international footprint. Cost-Effective and Affordable Solutions. Stringent quality control processes and complies with ISO standards and regulatory approvals.